Obeticholic acid-a new therapy in PBC and NASH
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Introduction: Obeticholic acid (OCA) is a semi-synthetic hydrophobic bile acid (BA) analogue that is highly selective agonist of farnesoid X receptor (FXR), a key nuclear BA receptor, which induces expression of gut-derived hormones, in particular fibroblast growth factor 19. The resulting beneficial effects of OCA on glucose and lipid metabolism and particularly hepatic inflammation make it a candidate for the treatment of a variety of conditions including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Sources of data: In PBC patients who have not initially responded to ursodeoxycholic acid, OCA has been shown in double-blind controlled clinical trials to significantly reduce serum alkaline phosphatase. To date, OCA is the only therapy licensed by the FDA, EMA and endorsed by NICE as second line therapy for PBC. No medications are currently approved in Europe or the USA for the treatment of NASH. In recent clinical trials, OCA has been shown encouraging results by improving liver blood tests and reducing liver fibrosis with no worsening of NASH. Areas of agreement: OCA is the established second line therapy for PBC in those patients who fail to adequately respond to ursodeoxycholic acid. Areas of controversy: The main side effects of OCA treatment in both PBC and NASH is that of dose-dependent pruritis which can lead to treatment discontinuation in ~1–10% of patients. In addition, OCA-treated patients may also exhibit (reversible) alterations in serum lipid levels; most notably a small decrease in high density lipoprotein cholesterol. It is not yet known whether these changes carry a long-term cardiovascular risk in NASH. In addition, the relatively high cost of OCA may limit its use in cash-limited health systems. Growing Points: Additional clinical trials are in progress to ascertain the long-term effects of OCA on survival in PBC and NASH. Areas timely for developing research: New FXR agonists with a lower rate of side effects are being developed and trialed. Combination therapy with other agents may offer increased efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FXR, a nuclear bile acid receptor, plays a central role in regulating bile acid homeostasis and stimulates the secretion of gut-derived hormones, particularly fibroblast growth factor 19 [26,27].”
From Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and Elafibranor (2025) · cites this paper as [26]
Citations
Cites
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Cited by
Items 101–119 of 119
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741363
Sun, L., Yang, N., Liu, Z., Ye, X., Cheng, M., Deng, L., Zhang, J., Wu, J., Shi, M., & Liao, W. (2024) · Figshare · doi:10.6084/m9.figshare.26741369
Haddad, E. M. (2024) · Corpus Université Laval (Université Laval)
La glucuronidation et la sulfatation des acides biliaires : plus qu'une voie d'inactivation?
Bellerive, E. (2023) · Corpus Université Laval (Université Laval)
Youssef, M. E., Shata, A., Abdelmaksoud, Y. T., Youssef, W., Awad, R. A., Sediek, H. H., Hasanin, E. M., Rashwan, B. M., Ghorabah, Y. O., Yehia, A., et al. (2026) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00926-z
“This farnesoid X receptor (FXR) agonist produces adverse effects such fatigue and pruritus, despite increasing bile secretion [18, 19].”
Morisseau, L. (2023) · theses.fr (ABES) · doi:10.70675/cfa5953ez697dz47bez9768zde0845d5a7b8 · Cited by 1
Wang, X., Jiang, Y., Feng, L., Luo, Y., Zhang, J., Wang, X., Wang, Y., Ma, Y., Hua, M., Jin, L., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158730
Inhibition of p107 alleviates liver steatosis by reducing de novo fatty acid synthesisPreprint
Cuñarro, J., Miguens, M. V., Diz, T. D. O., Buqué, X., Oro, L., Riobello, C., Iglesias-Moure, J., Quintela-Vilariño, C., Maduro, A. T., Cabaleiro, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.14.718271
Dąbrowska, A. M., Chwil, M., & Urbańska, E. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083081
“Pruritus can lead to treatment discontinuation in 1–10% of patients [30,61,63,64].”
InfluentialGanesh, T., subramani, V., Kannan, S. R., & Yuvaraj.G (2026) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2026.246617
“Recent global estimates (2024–2025) suggest that NAFLD affects nearly 30% of the 27, 2016 [15].”
Zhao, D., Cui, Y., & Hua, Z. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1783688
Mayo, A. K., Beaudoin, J. J., Woodhead, J. L., Watkins, P. B., & Brouwer, K. L. R. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70355 · Cited by 2
Zhou, H., Yang, J., Wu, W., Wei, S., ZHAO, Y., & Li, C. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2695704
“The most immediate impact of this research has been the approval of OCA, a semi-synthetic FXR agonist, for PBC, thus validating the therapeutic strategy of targeting BA homeostasis [126].”
Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when
Dražilová, S., Jarčuška, P., Koky, T., Harhovsky, M., Komarova, S., Vasil, J., & Janíčko, M. (2026) · World Journal of Hepatology · doi:10.4254/wjh.121491
Obeticholic Acid Rescues Male Reproductive Function in High-Fat Diet-Induced Metabolic Syndrome
Liu, J.-C., Zeng, Q., Li, D., Ma, T., Yeung, W. S. B., Zhang, T., & Duan, Y. (2026) · Reproductive Sciences · doi:10.1007/s43032-026-02180-x
Dietary flavonoids target the gut–liver axis for the management of cholestatic liver injury
白冬松, Fan, S.-Q., Mu, Y., Zheng, D., Huang, X., Ma, H., & Li, L. (2026) · Food & Function · doi:10.1039/d6fo03181a
Liu, J., Sun, K., Liu, H., Zhu, M., Li, C., He, Y., & Qin, L. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70318
Lee, A.-H., Lee, S. M., Kang, I. Y., Park, G. R., Yoo, H. H., Yu, J. S., Kim, H., Shin, J., Nam, Y., Yoon, E. L., et al. (2026) · Nutrients · doi:10.3390/nu18193296
“…has been approved by the U.S. Food and Drug Administration for the treatment of primary biliary cholangitis, its broader application in MASLD is limited due to the adverse effects associated with long-term therapy, particularly pruritus and OCA-induced elevation in serum cholesterol levels [14–16].”
Metadata
- Authors
- Chapman, R. W., & Lynch, K. D.
- Affiliations
- University of Oxford (GB)
- Royal Adelaide Hospital (AU)
- Corresponding author
- Chapman, Roger W
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-03
- Volume
- 133
- Issue
- 1
- Pages
- 95-104
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W3015589350
- Cited by
- 116
- References
- 25
- Citations by year
- 2026: 15 · 2025: 19 · 2024: 34 · 2023: 17 · 2022: 16 · 2021: 12 · 2020: 3
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- British Medical Bulletin (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- obeticholic acid, farnesoid X receptor agonist, primary biliary cirrhosis, nonalcoholic steatohepatitis, bile acid analogues, ursodeoxycholic acid, FGF19, pruritus, serum alkaline phosphatase, liver fibrosis, HDL cholesterol, cardiovascular risk, drug costs, combination therapy
- MeSH terms
- Receptor, Farnesoid X-Activated, Chenodeoxycholic Acid, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Treatment Outcome, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.